http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2061481-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9eaba309f79e4d31921b2aaae6ee6079 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bda0f8ef207d05bab322f9320325910 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_969b8616d26f6a341ca57c97f37d094a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e35032057b63fd22eb26fc44d47ed22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 1991-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6490253f1ec3bf83a3640c5d6b0314c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98609bf3be34feeeb7245895920b08fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bb91cb7d97e88c4225b438b31413adb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e148812527e0095e4e6610730ca052f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a9f57c2de924ae9129d12ef1f4a8b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d735817edbb2b5a0bd3cde375a0ec52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f0388a7de57f114994276cded2d276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76e32e9b81ac435ae72855a5afe6c0e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5106df05186000c4734a4b390a06614 |
| publicationDate | 1996-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2061481-C1 |
| titleOfInvention | Agent showing antiaggregation activity |
| abstract | FIELD: medicine, diabetology. SUBSTANCE: proposed agent is 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a] benzimidazole dihydrochloride showing hypoglycaemic activity. At the dose single dose 25 mg/kg compound decreases glucose content in animal with alloxane diabetes by 38% and after 10 day administration (25 mg/kg, every day) hypoglycaemic effect is increased by 1.5 fold. Hypoglycaemic potency of compound is equal with gliclazide, it exceeds that of maninil by 1.5 time and that of adebite by 2.4 times that are the known sugar-decreasing drugs. Duration of sugar-decreasing effect of proposed preparation corresponds with that of hypoglycaemic action of sulfonylurea derivatives, - gliclazide and maninil and exceeds this index of butylbiguanide derivative - adebite - by 3 times. Sugar-decreasing effect of substance is due to its stimulating effect on insulin secretion from β-cells of pancreas and potentiating (by 2.7 times) and prolonged (by 1.5 times) influence on hypoglycaemic action of this hormone. Compound is an active inhibitor of platelet aggregation and exceeds this effect of gliclazide and acetylsalicylic acid by 37 and 16.4 times, respectively, in vitro experiments. Antiaggregation effect of compound on intravessel platelet aggregation exceeds that of acetylsalicylic acid by 23.3 times. Proposed compound can be used for diabetes mellitus treatment, in part, at complicated states and used orally. EFFECT: increased effectiveness of new proposed antidiabetic agent. 3 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2485952-C2 |
| priorityDate | 1991-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.